Also Known As Singh
CEO of PerkinElmer
Singh is currently the President and Chief Executive Officer of PerkinElmer, Inc.(PKI) and brings more than twenty-five years of global leadership experience to Amphenol’s board. He was promoted to President and Chief Executive Officer of PerkinElmer effective December 30, 2019, and was appointed to its board of directors in 2019. Prior to his current role, he held various senior executive operating positions within PerkinElmer. Prior to joining PerkinElmer in 2014, Dr. Singh was a General Manager at GE Healthcare, and before that, Dr. Singh held senior executive level roles in strategy, business development and mergers & acquisitions at both GE Healthcare and Philips Healthcare. Earlier in his career, he held leadership roles of increasing responsibility at DuPont Pharmaceuticals and subsequently at Bristol-Myers Squibb Medical Imaging, which included managing the Asia Pacific and Middle East regions. Dr. Singh holds a doctoral degree in chemistry from the University of Missouri-Columbia and a Master of Business Administration degree from Northeastern University. His research work has resulted in several issued patents and publications in peer reviewed journals.
“Prahlad brings a wealth of experience to Amphenol, and we are excited to welcome him to Amphenol’s board of directors,” said R. Adam Norwitt, Amphenol’s President and CEO. “We believe his successful track record leading a large, publicly-traded U.S. multinational company, together with his extensive experience with technology and mergers and acquisitions will be extremely valuable as Amphenol continues to grow around the world.”
“We conducted an exhaustive search for a director who would further strengthen our board’s breadth of talent and background, and we are delighted to have identified such an outstanding individual,” said Martin Loeffler, Amphenol’s Chairman. “I am confident that Prahlad will make a significant contribution to our board and the Company.”
“I have been extremely impressed by Amphenol’s innovative products, dynamic leadership team and unique entrepreneurial culture, and am honored to be joining the board,” said Dr. Singh. “I have tremendous respect for Martin, Adam and the other board members, and I look forward to working with them.”